Literature DB >> 21178601

Economic costs of nonmedical use of prescription opioids.

Ryan N Hansen1, Gerry Oster, John Edelsberg, George E Woody, Sean D Sullivan.   

Abstract

OBJECTIVES: Although the economic costs of substance misuse have been extensively examined in the published literature, information on the costs of nonmedical use of prescription opioids is much more limited, despite being a significant and rapidly growing problem in the United States.
METHODS: We estimated the current economic burden of nonmedical use of prescription opioids in the United States in terms of direct substance abuse treatment, medical complications, productivity loss, and criminal justice. We distributed our broad cost estimates among the various drugs of misuse, including prescription opioids, down to the individual drug level.
RESULTS: In 2006, the estimated total cost in the United States of nonmedical use of prescription opioids was $53.4 billion, of which $42 billion (79%) was attributable to lost productivity, $8.2 billion (15%) to criminal justice costs, $2.2 billion (4%) to drug abuse treatment, and $944 million to medical complications (2%). Five drugs--OxyContin, oxycodone, hydrocodone, propoxyphene, and methadone--accounted for two-thirds of the total economic burden. DISCUSSION: The economic cost of nonmedical use of prescription opioids in the United States totals more than $50 billion annually; lost productivity and crime account for the vast majority (94%) of these costs.

Entities:  

Mesh:

Year:  2011        PMID: 21178601     DOI: 10.1097/AJP.0b013e3181ff04ca

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  57 in total

1.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

2.  Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III.

Authors:  Bradley T Kerridge; Tulshi D Saha; S Patricia Chou; Haitao Zhang; Jeesun Jung; W June Ruan; Sharon M Smith; Boji Huang; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2015-09-02       Impact factor: 4.492

3.  Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers.

Authors:  Kelly E Dunn; Kathryn A Saulsgiver; Mollie E Patrick; Sarah H Heil; Stephen T Higgins; Stacey C Sigmon
Journal:  Drug Alcohol Depend       Date:  2013-08-30       Impact factor: 4.492

4.  Chronic Opioid Usage in Surgical Patients in a Large Academic Center.

Authors:  Xueying Jiang; Margaret Orton; Rui Feng; Erik Hossain; Neil R Malhotra; Eric L Zager; Renyu Liu
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

5.  Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Drug Alcohol Depend       Date:  2012-02-25       Impact factor: 4.492

6.  Use and nonmedical use of prescription opioid analgesics in the general population of Canada and correlations with dispensing levels in 2009.

Authors:  Kevin D Shield; Wayne Jones; Jürgen Rehm; Benedikt Fischer
Journal:  Pain Res Manag       Date:  2013 Mar-Apr       Impact factor: 3.037

7.  Age of initiation, psychopathology, and other substance use are associated with time to use disorder diagnosis in persons using opioids nonmedically.

Authors:  Ty S Schepis; Jahn K Hakes
Journal:  Subst Abus       Date:  2017-07-19       Impact factor: 3.716

8.  Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial.

Authors:  D Max Crowley; Damon E Jones; Donna L Coffman; Mark T Greenberg
Journal:  Prev Med       Date:  2014-02-09       Impact factor: 4.018

Review 9.  The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

Authors:  Ann P Lin; Mei-Chuan Ko
Journal:  ACS Chem Neurosci       Date:  2012-11-06       Impact factor: 4.418

10.  The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013.

Authors:  Curtis S Florence; Chao Zhou; Feijun Luo; Likang Xu
Journal:  Med Care       Date:  2016-10       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.